Shares of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) rose 12.7% on Tuesday . The stock traded as high as $0.20 and last traded at $0.20. Approximately 782,286 shares traded hands during trading, a decline of 37% from the average daily volume of 1,248,948 shares. The stock had previously closed at $0.18.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lowered their price target on shares of Aridis Pharmaceuticals from $19.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, January 26th.
Aridis Pharmaceuticals Stock Up 12.7 %
The stock’s 50-day simple moving average is $0.32 and its 200 day simple moving average is $0.71. The company has a market cap of $6.02 million, a price-to-earnings ratio of -0.09 and a beta of 0.98.
Institutional Trading of Aridis Pharmaceuticals
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J.
- Get a free copy of the StockNews.com research report on Aridis Pharmaceuticals (ARDS)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.